This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More
by Kinjel Shah
Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.
The Zacks Analyst Blog Highlights AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale
by Zacks Equity Research
AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.
Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
by Zacks Equity Research
Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
by Zacks Equity Research
Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.
Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why
by Zacks Equity Research
Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy indication.
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ
by Zacks Equity Research
Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
by Zacks Equity Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Reasons Why You Should Invest in ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
by Zacks Equity Research
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Bruker (BRKR) International Growth Strong Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
The Zacks Analyst Blog Highlights Novo Nordisk, Intel, Qualcomm, T-Mobile US and Sony Group
by Zacks Equity Research
Novo Nordisk, Intel, Qualcomm, T-Mobile US and Sony Group are part of Zacks top Analyst Blog.
Here's Why Investors Should Retain Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
Top Analyst Reports for Novo Nordisk, Intel & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Intel Corporation (INTC), and Qualcomm Inc. (QCOM).
AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline
by Zacks Equity Research
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
Best Momentum Stocks to Buy for July 5th
by Zacks Equity Research
NVO and TMUS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 5, 2022.
New Strong Buy Stocks for July 5th
by Zacks Equity Research
CHS, PTMN, RYI, NVO and TMUS have been added to the Zacks Rank #1 (Strong Buy) List on July 5, 2022.
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
by Zacks Equity Research
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
LabCorp (LH) to Strengthen Laboratory Footprint in Japan
by Zacks Equity Research
LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.